202 related articles for article (PubMed ID: 29859044)
1. Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3β/β-catenin pathway.
Ng L; Chow AKM; Man JHW; Yau TCC; Wan TMH; Iyer DN; Kwan VHT; Poon RTP; Pang RWC; Law WL
BMC Cancer; 2018 Jun; 18(1):621. PubMed ID: 29859044
[TBL] [Abstract][Full Text] [Related]
2. Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3β/Wnt/β-catenin signaling.
Zhao G; Song Y; Dong L; Shi H; Li H; Yang L; Wang J
Biochem Biophys Res Commun; 2019 Oct; 517(4):722-728. PubMed ID: 31395338
[TBL] [Abstract][Full Text] [Related]
3. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
4. Zanthoxylum avicennae extract enhances GSK-3β to attenuate β-catenin via phosphatase 2A to block metastatic effects of HA22T cells and hepatocellular carcinoma xenografted nude mice.
Wu HC; Lay IS; Shibu MA; Ho TJ; Cheng SM; Lin CH; Dung TD; Jeng LB; Viswanadha VP; Huang CY
Environ Toxicol; 2017 Sep; 32(9):2133-2143. PubMed ID: 28548306
[TBL] [Abstract][Full Text] [Related]
5. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Liu Y; Ye X; Zhang JB; Ouyang H; Shen Z; Wu Y; Wang W; Wu J; Tao S; Yang X; Qiao K; Zhang J; Liu J; Fu Q; Xie Y
Oncogene; 2015 Oct; 34(44):5524-35. PubMed ID: 25684142
[TBL] [Abstract][Full Text] [Related]
6. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
7. Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of β-catenin/TCF/LEF signalling.
Gao H; Yin FF; Guan DX; Feng YX; Zheng QW; Wang X; Zhu M; Zhang XL; Cheng SQ; Chen TW; Jiang H; Zhang EB; Wang JJ; Ni QZ; Yuan YM; Zhang FK; Ma N; Cao HJ; Wang YK; Li JJ; Xie D
Cell Prolif; 2019 May; 52(3):e12583. PubMed ID: 30793395
[TBL] [Abstract][Full Text] [Related]
8. Down-regulated PLAC8 promotes hepatocellular carcinoma cell proliferation by enhancing PI3K/Akt/GSK3β/Wnt/β-catenin signaling.
Zou L; Chai J; Gao Y; Guan J; Liu Q; Du JJ
Biomed Pharmacother; 2016 Dec; 84():139-146. PubMed ID: 27643556
[TBL] [Abstract][Full Text] [Related]
9. HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3β signaling pathways.
Chen T; Huang H; Zhou Y; Geng L; Shen T; Yin S; Zhou L; Zheng S
J Exp Clin Cancer Res; 2018 Aug; 37(1):193. PubMed ID: 30111352
[TBL] [Abstract][Full Text] [Related]
10. Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma.
Lin X; Li AM; Li YH; Luo RC; Zou YJ; Liu YY; Liu C; Xie YY; Zuo S; Liu Z; Liu Z; Fang WY
Signal Transduct Target Ther; 2020 Feb; 5(1):13. PubMed ID: 32296025
[TBL] [Abstract][Full Text] [Related]
11. Dickkopf 4 (DKK4) acts on Wnt/β-catenin pathway by influencing β-catenin in hepatocellular carcinoma.
Fatima S; Lee NP; Tsang FH; Kolligs FT; Ng IO; Poon RT; Fan ST; Luk JM
Oncogene; 2012 Sep; 31(38):4233-44. PubMed ID: 22249261
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling.
Quan H; Li B; Yang J
Biomed Pharmacother; 2018 Nov; 107():754-762. PubMed ID: 30142536
[TBL] [Abstract][Full Text] [Related]
13. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway.
Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J
Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804
[TBL] [Abstract][Full Text] [Related]
14. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
Peng YY; He YH; Chen C; Xu T; Li L; Ni MM; Meng XM; Huang C; Li J
Cancer Lett; 2016 Jun; 376(1):10-21. PubMed ID: 26975630
[TBL] [Abstract][Full Text] [Related]
15. AMPK interacts with β-catenin in the regulation of hepatocellular carcinoma cell proliferation and survival with selenium treatment.
Park SY; Lee YK; Kim HJ; Park OJ; Kim YM
Oncol Rep; 2016 Mar; 35(3):1566-72. PubMed ID: 26707164
[TBL] [Abstract][Full Text] [Related]
16. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma.
Yang YF; Pan YH; Cao Y; Fu J; Yang X; Zhang MF; Tian QH
Oncotarget; 2017 Jul; 8(29):47195-47205. PubMed ID: 28525379
[TBL] [Abstract][Full Text] [Related]
17. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.
Zheng Y; Jiang L; Hu Y; Xiao C; Xu N; Zhou J; Zhou X
BMC Cancer; 2017 Feb; 17(1):161. PubMed ID: 28241806
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma.
Wu G; Zheng K; Xia S; Wang Y; Meng X; Qin X; Cheng Y
J Exp Clin Cancer Res; 2016 Jun; 35(1):89. PubMed ID: 27259866
[TBL] [Abstract][Full Text] [Related]
19. DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/β-catenin signaling.
Liu Y; Zhou R; Yuan X; Han N; Zhou S; Xu H; Guo M; Yu S; Zhang C; Yin T; Wu K
Oncotarget; 2015 Apr; 6(11):8621-34. PubMed ID: 25940701
[TBL] [Abstract][Full Text] [Related]
20. Lectin BS-I inhibits cell migration and invasion via AKT/GSK-3β/β-catenin pathway in hepatocellular carcinoma.
Jian Q; Yang Z; Shu J; Liu X; Zhang J; Li Z
J Cell Mol Med; 2018 Jan; 22(1):315-329. PubMed ID: 28922551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
